Clearmind Medicine Announces Three U.S. Patent Applications Covering Novel Proprietary Combinations Of LSD, Ketamine And Ibogaine With N-Acylethanolamines Such As Palmitoylethanolamide

Clearmind Medicine has announced three U.S. patent applications for novel combinations of LSD, ketamine, and ibogaine with N-acylethanolamines, targeting therapeutic uses for mental health disorders, pain, and substance use disorders. This development is part of an ongoing collaboration with NeuroThera Labs, which has led to a growing portfolio of patent applications. The company aims to create effective treatments at lower doses, potentially improving tolerability while maintaining therapeutic efficacy.